HYBRITECH TANDEM PSA TEST APPROVED AS DIAGNOSTIC AID
This article was originally published in The Gray Sheet
Executive SummaryHYBRITECH TANDEM PSA TEST APPROVED AS DIAGNOSTIC AID in the detection of prostate cancer. The Tandem-R (immunoradiometric), Tandem-E (immunoenzymetric) and Tandem-ERA (automated enzyme immunoassay) assays for quantitative prostate specific antigen measurement become the first PSA blood tests approved for use in detecting the disease.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.